BioCentury | Nov 21, 2020
Regulation

Nov. 20 Quick Takes: Approvals in Europe for Alnylam, Alexion therapies; plus FDA priority review for ADC, Sanofi and more

EC approves Alnylam, Alexion therapiesAlnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the European Commission approved Oxlumo lumasiran, an RNAi therapy targeting the HAO1 mRNA that encodes glycolate oxidase, to treat primary hyperoxaluria in all age groups. The...
BioCentury | Nov 21, 2020
Product Development

Could an approval of Biogen’s Alzheimer’s therapy still be an option?

For almost any other compound, the nearly unanimous advisory committee vote that Biogen’s Alzheimer’s therapy aducanumab suffered would make its chances of approval vanishingly small. But this mAb...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Nov 21, 2020
Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety...
BioCentury | Nov 20, 2020
Regulation

WHO counters FDA as it recommends against Veklury for COVID-19

The WHO’s new guidance counters FDA’s October approval of Gilead’s Veklury for hospitalized patients, adding to the debate around the drug’s use and variable performance in randomized, controlled trials. In The BMJ on Thursday, the WHO issued a...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

In an award ceremony recognizing eight achievements in the life sciences in China this year, BayHelix highlighted the rapid growth of financing and deals by China’s biopharma companies. Innovent took home the Company of the Year...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

The latest in a growing list of Chinese biopharma “money magnets,” D3 Bio has made its official launch with a strategy that reflects emerging trends in the sector, which include moving away from me-too pipelines, relying...
BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

Metagenomi is systematizing the search for new gene editing tools by scouring the genomes of bacteria in ecological samples. The company emerged from stealth Thursday with a $65 million series A round...
Items per page:
1 - 10 of 7767